Checkpoint Inhibition in Myeloma: Opportunities and Challenges
Federica Costa(University of Parma), Madhav V. Dhodapkar(Emory University)
Cited by 62
Related Papers
Classification of current anticancer immunotherapies
|Oncotarget|2014|469
Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy
|JCI Insight|2019|167
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
|Clinical Cancer Research|2011|109
Natural immunity to pluripotency antigen OCT4 in humans
|Proceedings of the National Academy of Sciences|2010|90
Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
|Cancer Research Communications|2022|40